Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
Public ClinicalTrials.gov record NCT02690701. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Secukinumab on Aortic Vascular Inflammation and Cardiometabolic Biomarkers After 12 Weeks of Treatment, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
Study identification
- NCT ID
- NCT02690701
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 91 participants
Conditions and interventions
Conditions
Interventions
- Placebo Biological
- Secukinumab 300 mg Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 9, 2016
- Primary completion
- Apr 25, 2017
- Completion
- Feb 18, 2018
- Last update posted
- Jan 4, 2021
2016 – 2018
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Los Angeles | California | 90033 | — |
| Novartis Investigative Site | Santa Ana | California | 92701 | — |
| Novartis Investigative Site | Rockville | Maryland | 20850 | — |
| Novartis Investigative Site | St Louis | Missouri | 63117 | — |
| Novartis Investigative Site | Buffalo | New York | 14221 | — |
| Novartis Investigative Site | New York | New York | 10025 1737 | — |
| Novartis Investigative Site | Portland | Oregon | 97223 | — |
| Novartis Investigative Site | Portland | Oregon | 97239 | — |
| Novartis Investigative Site | Exton | Pennsylvania | 19341 | — |
| Novartis Investigative Site | Dallas | Texas | 75246-1613 | — |
| Novartis Investigative Site | Houston | Texas | 77004 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02690701, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 4, 2021 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02690701 live on ClinicalTrials.gov.